• Over the years, the healthcare industry has witnessed regulatory approvals of innovative technologies in oncology without head-to-head clinical trial evidence or Health Related Quality-of-Life (HRQoL) data.
• This yields a challenge to decision-makers who require a cost-effectiveness analysis (CEA) to conduct Health Technology Assessments.
• We present a case study using recently approved drugs lenvatinib and sorafenib for management of radioiodine-refractory differentiated thyroid cancer (RR-DTC) in order to demonstrate methodological approaches and potential data sources to address these gaps.
RESULTS

Figure 1: Mean observed utilities for RR-DTC health states and calculated incremental disutilities
• The final health state utilities for the response and stable health state were higher for patient on lenvatinib as compared to patients on sorafenib which favors patients taking lenvatinib (Table 2 & 3)
• The final health state utilities in the stable disease and the response health states were lower for patients taking sorafenib which also favors patients taking lenvatinib (Table 3) • MAITC yielded the Hazard Ratio (HR) of lenvatinib/sorafenib post RPSFT correction as 0.73 for overall survival (OS) and 0.32 for progression free survival (PFS) [4] • The undiscounted Quality Adjusted Life Years were consistently found to be greater for patients on Lenvatinib as compared to patients on Sorafenib ( Figure 2) • The total progression free life years, life years saved and quality adjusted life years saved were also greater for patients on lenvatinib as compared to patients on sorafenib (Table 4) Figure 2 : Undiscounted QALYs per month for Lenvatinib and Sorafenib over a period of ten years Table 4 : Incremental Effectiveness over a period of 10 years (Undiscounted)
OBJECTIVE
• To demonstrate methodological approaches and potential data sources to assist the decision making process of Health Technology Assessment bodies in the absence of head-to-head clinical trials and HRQoL data.
METHODS
• Systematic literature review has revealed that Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) and Study of Sorafenib in Locally Advanced or Metastatic Patients with Radioiodine-Refractory Thyroid Cancer (DECISION) were the only two randomized clinical trial (RCT) studies performed within progressive RR-DTC patients.
• Phase 3 Randomized Controlled Trials (RCTs) of both lenvatinib and sorafenib compared treatments to placebo; no head-to-head comparison data were available.
• Some notable commonalities in the study design / disease characteristics of the two study populations are as follows: • HRQoL and Utility were not collected in SELECT trial but were collected in the DECISION trial. However, literature search did not yield any published health state utility or AE disutility data for HRQoL of patients in DECISION trial.
• Hence, following techniques were used to compare the data in the two trials:
-Vignette Studies
-Matched Indirect Treatment Comparison
Vignette Studies
• A vignette study was conducted to elicit utilities for RR-DTC health-states and estimate the impact of toxicities on HRQoL on general population in UK
• A list of health states, was finalised using feedback provided by the clinical experts and included: stable/no response, response (partial and complete), progressive disease, stable/no response with grade III diarrhoea, stable/no response with grade III fatigue, stable/no response with grade III hand-foot syndrome (HFS) and, stable/no response with grades I and II alopecia.
• Additional adverse events to those listed in the health states were discussed however, concluded to be less relevant to the HRQoL of patients with RR-DTC. For example, while hypertension was reported as a relatively common event, it was not included in this analysis; nurse and clinician opinion was that hypertension is asymptomatic in the majority of patients, therefore exerting little effect on HRQoL.
• Final health states underwent valuation by 100 participants from the general public during a face-to-face interviews using a 0-100 visual analogue scale (VAS) and a time trade off (TTO) valuation method.
Matched Indirect Treatment Comparison
• Data from the SELECT trial (lenvatinib vs placebo) were subjected to MAIC to ensure comparability with the DECISION trial (sorafenib vs placebo).
• Data for individual patients in SELECT were assigned weights so that the weighted mean baseline characteristics of the SELECT population matched those reported for DECISION.
• Subjects in SELECT, who had received prior VEGF/VEGFR-targeted therapy were removed from the ITC analysis since including these patients could have created a bias as the sample would include patients that have different inclusion criteria.
• Adjusted hazards ratios (HRs) for progression-free survival (PFS) and overall survival (OS) were calculated using Cox regression models with weights generated using propensity scores.
• Adjusted HRs were used to calculate indirect HRs with 95% confidence intervals (CIs).
• RPSFT-adjusted OS data for both treatments were used in the ITC analysis.
Survival Data Extrapolation and Effectiveness Analysis
• Extrapolation of survival data was required since the trial data prior to cut-off did not provide enough information on overall survival and progression free survival in oncology [3] • An updated dataset from the Select study (June 2014) was used to obtain patient specific data on tumour response, PFS and OS and was used for extrapolation. [4] • Patient who were lost to follow-up and withdrawn were removed from the dataset. The RPSFT-adjusted OS data was used as the base case scenario in extrapolation. [4] • Quality Adjusted Life Years were further calculated for patients on Lenvatinib and Sorafenib by multiplying the utilites with the extrapolated OS data for the respective drugs
LIMITATIONS
• Both studies allowed for cross-over and the data were corrected using RPSFT method, this may have introduced some bias in the study results.
• Vignette study was conducted in general UK population and may not reflect true utilities for RR-DTC population or other cultures.
• Most importantly, this study does not adjust for unobserved confounding factors, which could explain the effect along with the treatment difference. Furthermore, in addition to confounding factors not observed in either trial, it also fails to match on factors not observed in BOTH trials.
CONCLUSION
• For this case study of lenvatinib vs. sorafenib, the mean observed adverse event disutilities were lower for patients on lenvatinib as compared to patients on sorafenib.
• All the health state utilities and disutilities were in favor of patients on lenvatinib.
• Furthermore, the outcomes such as progression free survival, Life years saved and quality adjusted life years were also in favor of patients taking lenvatinib.
• These analysis and results demonstrated that in absence of head-to-head trials and HRQoL trial data, vignette utility studies and ITC may be used to aid with QALY analysis.
• These techniques may be used in orphan diseases where limited data are available.
• While vignette studies and ITC can increase reliability of comparative-effectiveness data and support payers' decision making, collection of trial and real-world HRQoL data and head-to-head analysis should be performed when possible.
• • Brose et al., Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial., ASCO, 2014
RESULTS
Vignette Study Results
• Mean utility values derived from the TTO interviews indicate how participants in the study differentiated between the RR-DTC health states ( Table 2 ,3, Figure 1 ).
• The incremental impact of health states on utilities was then derived compared to a base state of stable/no response with no adverse events ( Table 2 ,3, Figure  1 ) Table 2 : AE-related Product specific disutilities 
